Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.

Literature DB >> 7083463

Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.

F C Schell, H Y Yap, G N Hortobagyi, B Issell, L Esparza.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Etoposide
Podophyllotoxin

Year: 1982 PMID： 7083463 DOI： 10.1007/BF00254555

Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333

× No keyword cloud information.

10 in total

1. Combination chemotherapy for advanced breast cancer: response and effect on survival.

Authors: G P Canellos; V T DeVita; G L Gold; B A Chabner; P S Schein; R C Young
Journal: Ann Intern Med Date: 1976-04 Impact factor: 25.391

Review 2. The chemical therapy of breast cancer.

Authors: S K Carter
Journal: Semin Oncol Date: 1974-06 Impact factor: 4.929

3. Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors.

Authors: H Stähelin
Journal: Eur J Cancer Date: 1973-03 Impact factor: 9.162

4. Chemo immunotherapy of advanced breast cancer with BCG.

Authors: G N Hortobagyi; J U Gutterman; G R Blumenschein; A Buzdar; M A Burgess; S P Richman; C K Tashima; M Schwarz; E M Hersh
Journal: Recent Results Cancer Res Date: 1977

5. Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.

Authors: S E Jones; B G Durie; S E Salmon
Journal: Cancer Date: 1975-07 Impact factor: 6.860

6. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.

Authors: M De Lena; C Brambilla; A Morabito; G Bonadonna
Journal: Cancer Date: 1975-04 Impact factor: 6.860

7. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer.

Authors: H Y Yap; G R Blumenschein; M J Keating; G N Hortobagyi; C K Tashima; T L Loo
Journal: Cancer Treat Rep Date: 1980 Feb-Mar

8. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer.

Authors: H Y Yap; R S Benjamin; G R Blumenschein; G N Hortobagyi; C K Tashima; A U Buzdar; G P Bodey
Journal: Cancer Treat Rep Date: 1979-01

Review 9. Etoposide (VP-16-213).

Authors: B F Issell; S T Crooke
Journal: Cancer Treat Rev Date: 1979-06 Impact factor: 12.111

10. Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy.

Authors: A U Buzdar; C K Tashima; G R Blumenschein; G N Hortobagyi; H Y Yap; A N Krutchik; G P Bodey; R B Livingston
Journal: Cancer Date: 1978-02 Impact factor: 6.860

10 in total

7 in total

1. Phase I-II study of high-dose etoposide in patients with refractory breast cancer.

Authors: G Fraschini; F A Holmes; L Esparza; R L Theriault; A U Buzdar; G N Hortobagyi
Journal: Invest New Drugs Date: 1991-11 Impact factor: 3.850

2. Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer.

Authors: M Bontenbal; A S Planting; J Verweij; R de Wit; W H Kruit; G Stoter; J G Klijn
Journal: Breast Cancer Res Treat Date: 1995-05 Impact factor: 4.872

Review 3. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors: J M Henwood; R N Brogden
Journal: Drugs Date: 1990-03 Impact factor: 9.546